JP2024536821A5 - - Google Patents
Info
- Publication number
- JP2024536821A5 JP2024536821A5 JP2024518385A JP2024518385A JP2024536821A5 JP 2024536821 A5 JP2024536821 A5 JP 2024536821A5 JP 2024518385 A JP2024518385 A JP 2024518385A JP 2024518385 A JP2024518385 A JP 2024518385A JP 2024536821 A5 JP2024536821 A5 JP 2024536821A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- polypeptide
- enpp1
- polysorbate
- reconstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248303P | 2021-09-24 | 2021-09-24 | |
| US63/248,303 | 2021-09-24 | ||
| PCT/US2022/076969 WO2023049864A1 (en) | 2021-09-24 | 2022-09-23 | Lyophilized enpp1 polypeptide formulations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536821A JP2024536821A (ja) | 2024-10-08 |
| JP2024536821A5 true JP2024536821A5 (https=) | 2025-09-25 |
Family
ID=85721287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518385A Pending JP2024536821A (ja) | 2021-09-24 | 2022-09-23 | 凍結乾燥されたｅｎｐｐ１ポリペプチド製剤及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250073319A1 (https=) |
| EP (1) | EP4404980A4 (https=) |
| JP (1) | JP2024536821A (https=) |
| KR (1) | KR20240064707A (https=) |
| CN (1) | CN118215507A (https=) |
| AU (1) | AU2022353101A1 (https=) |
| CA (1) | CA3231858A1 (https=) |
| CO (1) | CO2024004755A2 (https=) |
| IL (1) | IL311578A (https=) |
| MX (1) | MX2024003506A (https=) |
| TW (1) | TW202330017A (https=) |
| WO (1) | WO2023049864A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4414028A3 (en) * | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| US12134790B2 (en) * | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| CA3126839A1 (en) * | 2019-01-18 | 2020-07-23 | Inozyme Pharma, Inc. | Treatment of diseases involving deficiency of enpp1 or enpp3 |
| CA3195071A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
-
2022
- 2022-09-23 CA CA3231858A patent/CA3231858A1/en active Pending
- 2022-09-23 WO PCT/US2022/076969 patent/WO2023049864A1/en not_active Ceased
- 2022-09-23 TW TW111136212A patent/TW202330017A/zh unknown
- 2022-09-23 EP EP22873898.5A patent/EP4404980A4/en active Pending
- 2022-09-23 JP JP2024518385A patent/JP2024536821A/ja active Pending
- 2022-09-23 AU AU2022353101A patent/AU2022353101A1/en active Pending
- 2022-09-23 MX MX2024003506A patent/MX2024003506A/es unknown
- 2022-09-23 IL IL311578A patent/IL311578A/en unknown
- 2022-09-23 KR KR1020247012631A patent/KR20240064707A/ko active Pending
- 2022-09-23 CN CN202280074276.7A patent/CN118215507A/zh active Pending
-
2024
- 2024-03-21 US US18/612,571 patent/US20250073319A1/en active Pending
- 2024-04-16 CO CONC2024/0004755A patent/CO2024004755A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230047111A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| US12460014B2 (en) | Antibody-containing preparation | |
| KR950014915B1 (ko) | 탈시알로당단백-포함화합물 | |
| ES2906550T3 (es) | Administración subcutánea de ADAMTS13 | |
| TW201021825A (en) | Lyophilized recombinant VWF formulations | |
| AU2018334502A1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| US20230039268A1 (en) | Anti-pd-l1 antibody formulations | |
| JP2022530050A5 (https=) | ||
| AU2020270046B2 (en) | Alkaline phosphate-based oncology treatments | |
| US20260069688A1 (en) | Stable antibody composition | |
| AU2020311050B2 (en) | Stable formulations of recombinant proteins | |
| EP0612530B1 (en) | Pharmaceutical preparations containing tumor cytotoxic factor | |
| JP2024536821A5 (https=) | ||
| RU2024111069A (ru) | Лиофилизированные препараты полипептида enpp1 и их применение | |
| TW202606715A (zh) | 治療成骨不全之方法 | |
| RU2855065C1 (ru) | Составы на основе антитела к pd-l1 | |
| RU2024121592A (ru) | Лиофилизированная композиция, содержащая слитый белок, включающий α-галактозидазу А | |
| RU2776108C2 (ru) | Лиофилизированный состав на основе hgf | |
| RU2024121587A (ru) | ЖИДКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК, ВКЛЮЧАЮЩИЙ α-ГАЛАКТОЗИДАЗУ A | |
| RU2021133921A (ru) | Стабильные маловязкие составы на основе антитела и пути их применения | |
| NZ712440B2 (en) | Subcutaneous administration of adamts13 | |
| OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| NZ749570B2 (en) | Subcutaneous administration of adamts13 |